Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
PDK4 overexpression
Cancer:
Diffuse Large B Cell Lymphoma
Drug:
Rituxan (rituximab)
(
CD20 inhibitor
)
Direction:
Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Cancer Sci
Title:
PDK4-mediated metabolic reprogramming is involved in rituximab resistance in DLBCL via affecting the expression of MS4A1/CD20
Published date:
07/12/2021
Excerpt:
We found that overexpression of PDK4 in DLBCL cells resulted in cell proliferation and resistance to rituximab in vitro and in vivo.
DOI:
10.1111/cas.15055
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login